REFERENCES

1. World Health Organization, Global Tuberculousis CONTROL. WHO report, 2001. geneva Switzerland: WHO/CDS/TB, 2001.287.
2. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assocphysicians India 1991; 39: 595-6.
3. Govt. Of India (2006), Annual Report 2005-2006, Ministry Of Health and Family Welfare, New delhi
4. Govt. Of India (2006), T.B. India 2006, RNTCP status report, DOT’s for All for DOT’s Ministry Of Health and Family Welfare, New Delhi.
5. Vidal R, Rey R, Espnar A, et al. treatment and retreatment of tuberculosis. Arch Bronconeumol 1996: 32: 463-474.
6. Pande J N, singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
7. American thoracic society, centres for disease control and prevention and infectious disease society of America: treatment of tuberculosis. Am J respirecrity care med 2003; 167: 603-662.
8. Gronhagen – Riska, C., P.E. Hellstrom, and B. froseth. 1978. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. Am. Rev. Respir. Dis 118: 461-466.
9. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of Tuberculosis chemotherapy under general conditions in Singapore. Int J Tuberc Lung Dis 2000; 6: 699-705.
10. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. evaluation of clinical and immuunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J RespirCrit Care Med 2002; 166-119.
11. Pande J N, singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136
12. Huang Y S, Chern H D, Su W J, et al. polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug induced hepatitis. Hepatology 2002; 35:885-889.
13. Devoto F M, Gonzalez C, lannantuono R, Serra H A, Gonazalez; C D, Saenz acta. PhysiolPharmacolTherLatinoam; 1997; 47: 197-202.
14. Gilrory S A, Rogers M A, Blair D C. Treatment of Latent Tuberculosis infection in patients aged. 35 years. Clin Infect Dis. 2000; 31: 826-829.
15. Stevens, C.E., P.E. Taylor, J. Pindyck, Q.L. Choo, D.W. Bradley, G. Kuo, and M. Houghlon. 1990. Epidemiology of hepatitis C virus: a preliminary study in volunteer blood donors. J.A.M.A. 263: 49-53.
16. Alter, M. J., 1994. Transmission of hepatitis C virus: route, dose and titer, N. Engl. J. Med. 330L 784
17. Bailey, W.C., S.L. Taylor, H.E. Dascomb, H.B. Greenberg, and M.M. Ziskind. 1973. Disturbed hepatic function during isoniazid chemoprophylaxis. Am. Rev. Respir. Dis. 107: 523-529.
18. Taneja DP, Kaur D. Desprez RM. Hepatitis with isoniazid and rifampicin; antituberculosis drugs. J Indian med assoc 1990; 88:278-80.
19. Gurumurthy p, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58-61.
20. Wong WM, Wu PC, Yuen MF, et al. antituberculosis drug related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 3; 201-206.
21. Deshpande DV, Nachne D, Koyande D, Rodrigues CJ. Antitubercular Physicians india 1991; 39: 599-601.
22. Singh J, Garg PK, Tandon RK, Hepatotxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J ClinGastroenterology 1996; 22(3): 211-4.
23. Taneja DP, Kaur D. Desprez RM. Hepatitis with isoniazid and rifampicin; antituberculosis drugs. J Indian med assoc 1990; 88:278-80.
24. Steele MA, Burk RF, Desprez RM. Hepatitis with insoniazid and rifampicin; a meta-analysis. Chest 1991; 99:465-71.
25. Kopanoff DE, Snider D, Caras G. Isoniazid related hepatitis: a U.S. Public Health Service Cooperative surveillance study. Am. Rev. Respir. Dis; 1979; 117: 991-1001.